Mural Oncology plc (MURA) Stock Analysis
DELISTED 2025
What happened to Mural Oncology plc (MURA) stock?
Mural Oncology plc (MURA) no longer trades on public markets. It was delisted in December 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mural Oncology plc (MURA) trades at $2.04. Mural Oncology Plc is a clinical-stage oncology company focused on discovering and developing immunotherapies for cancer treatment. Market cap: $35.4M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for MURA: MURA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MURA against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
MURA: this read rests on a single discipline (Legends Council) — the other council disciplines have no scored data yet.
How is this calculated? →Mural Oncology plc (MURA) Healthcare & Pipeline Overview
Mural Oncology Plc, a clinical-stage biotechnology company, specializes in developing innovative immunotherapies for cancer. Their lead candidate, nemvaleukin alfa, addresses unmet needs in mucosal melanoma and platinum-resistant ovarian cancer. With a focused pipeline and experienced leadership, Mural Oncology aims to improve patient outcomes in targeted oncology indications.
What Is the Investment Thesis for MURA?
Mural Oncology presents a focused investment opportunity within the biotechnology sector, driven by its clinical-stage immunotherapy pipeline. The primary value driver is the advancement of nemvaleukin alfa through clinical trials, targeting mucosal melanoma and platinum-resistant ovarian cancer. Success in these trials, particularly demonstrating statistically significant efficacy and safety data, could lead to accelerated regulatory approval and market adoption. Key catalysts include upcoming clinical trial readouts and potential partnerships for further development and commercialization. A potential risk lies in the inherent uncertainty of clinical trials and regulatory processes, as well as competition from established pharmaceutical companies in the oncology space. With a market capitalization of $35.4M and a negative P/E ratio of -0.30, Mural Oncology's valuation is highly dependent on the successful execution of its clinical development programs.
Based on FMP financials and quantitative analysis
MURA Key Highlights
Lead product candidate, nemvaleukin alfa, targets mucosal melanoma as a monotherapy.
- Nemvaleukin alfa is also being developed in combination with pembrolizumab for platinum-resistant ovarian cancer.
- The company is developing engineered interleukin-18 and tumor-targeted interleukin-12 programs.
- Mural Oncology operates as a former subsidiary of Alkermes plc as of November 15, 2023.
- The company is based in Dublin, Ireland, with 116 employees.
Who Are MURA's Competitors?
MURA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATHE Alterity Therapeutics Limited | $4.64 | -3.33% | $78.6M | 58 |
| BCAB BioAtla, Inc. | $3.18 | -2.75% | $5.28M | — |
| BTAI BioXcel Therapeutics, Inc. | $0.83 | +4.46% | $25.6M | — |
| EVAX Evaxion Biotech A/S | $3.28 | +4.13% | $20.7M | 66 |
| GBIO Generation Bio Co. | $5.34 | +0.00% | $36.0M | 69 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MURA's Key Strengths?
Novel immunotherapy pipeline.
- Lead product candidate in clinical development.
- Experienced management team.
- Focus on unmet needs in oncology.
What Are MURA's Weaknesses?
Clinical-stage company with no approved products.
- Limited financial resources.
- High dependence on clinical trial outcomes.
- Small number of employees.
What Could Drive MURA Stock Higher?
Clinical trial readouts for nemvaleukin alfa in mucosal melanoma.
- Clinical trial readouts for nemvaleukin alfa in platinum-resistant ovarian cancer.
- Initiation of clinical trials for engineered interleukin-18 program.
- Announcement of strategic partnerships or collaborations.
- Advancement of tumor-targeted interleukin-12 program through preclinical studies.
What Are the Key Risks for MURA?
Financial-distress signal — its Altman Z-Score of -8.23 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $3.9M recently.
- Clinical trial failures for nemvaleukin alfa or other pipeline candidates.
- Competition from established pharmaceutical companies with approved oncology therapies.
- Regulatory delays or rejections.
- Economic downturn impacting funding for biotechnology companies.
- Dependence on successful execution of clinical development programs.
What Are the Growth Opportunities for MURA?
- Expansion of Nemvaleukin Alfa: Mural Oncology has the opportunity to expand the application of nemvaleukin alfa beyond mucosal melanoma and platinum-resistant ovarian cancer. Exploring its potential in other solid tumors or hematological malignancies could significantly increase its market reach. The global solid tumor market is projected to reach $450 billion by 2030, presenting a substantial opportunity for Mural Oncology if nemvaleukin alfa demonstrates efficacy in additional indications. This expansion would require further clinical trials and regulatory approvals, with a timeline of 3-5 years.
- Advancement of Engineered Interleukin-18 Program: The development of engineered interleukin-18 (IL-18) represents another significant growth opportunity. IL-18 is a potent immune stimulator, and Mural Oncology's engineered version could offer improved efficacy and safety compared to existing approaches. The market for IL-18-based therapies is nascent but holds significant potential, with estimates suggesting a market size of $5 billion by 2032. Clinical trials for the IL-18 program are expected to commence within the next 2 years, with potential for accelerated development based on early results.
- Development of Tumor-Targeted Interleukin-12 Program: Mural Oncology's tumor-targeted interleukin-12 (IL-12) program offers a targeted approach to cancer immunotherapy. By delivering IL-12 directly to the tumor microenvironment, the company aims to minimize systemic toxicity and maximize anti-tumor activity. The market for targeted immunotherapies is growing rapidly, with a projected value of $30 billion by 2028. Preclinical studies are ongoing, with plans to initiate clinical trials within the next 3 years. Successful development could position Mural Oncology as a leader in targeted cancer immunotherapy.
- Strategic Partnerships and Collaborations: Mural Oncology can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline. Partnering with larger pharmaceutical companies could provide access to resources, expertise, and global market reach. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation, with deal values reaching record levels in recent years. Mural Oncology is actively seeking partnerships, with potential deals expected to be announced within the next 1-2 years. These partnerships could provide significant financial and strategic benefits.
- Geographic Expansion: While currently based in Dublin, Ireland, Mural Oncology has the opportunity to expand its geographic presence to key markets such as the United States and Europe. Establishing a presence in these regions would facilitate clinical trial recruitment, regulatory interactions, and commercialization efforts. The US and European markets account for over 70% of global pharmaceutical sales, representing a significant growth opportunity. Mural Oncology is evaluating potential expansion options, with plans to establish a US presence within the next 2-3 years.
What Are MURA's Competitive Advantages?
- Proprietary immunotherapy technologies.
- Patent protection for nemvaleukin alfa and other pipeline candidates.
- Clinical data demonstrating efficacy and safety.
- Experienced management team with expertise in oncology drug development.
What Does MURA Do?
Mural Oncology Plc, incorporated in 2017 and based in Dublin, Ireland, is a clinical-stage oncology company dedicated to discovering and developing novel immunotherapies for cancer patients. Spun out from Alkermes plc on November 15, 2023, Mural Oncology is focused on advancing its pipeline of innovative cancer treatments. The company's lead product candidate, nemvaleukin alfa, is being developed as a monotherapy for mucosal melanoma and in combination with pembrolizumab for platinum-resistant ovarian cancer. Additionally, Mural Oncology is developing engineered interleukin-18 and tumor-targeted interleukin-12 programs to further expand its therapeutic offerings. Mural Oncology's strategic focus on immunotherapies aims to harness the body's own immune system to fight cancer, offering potentially more effective and durable treatment options. The company operates with a team of 116 employees, managing its research and development efforts from its headquarters in Dublin.
What Products and Services Does MURA Offer?
- Discovers and develops immunotherapies for cancer treatment.
- Focuses on harnessing the body's immune system to fight cancer.
- Develops nemvaleukin alfa as a monotherapy for mucosal melanoma.
- Develops nemvaleukin alfa in combination with pembrolizumab for platinum-resistant ovarian cancer.
- Engineers interleukin-18 for improved efficacy and safety.
- Creates tumor-targeted interleukin-12 programs for localized treatment.
How Does MURA Make Money?
- Develops and patents novel immunotherapies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from health authorities.
- Potentially commercializes therapies directly or through partnerships.
What Industry Does MURA Operate In?
Mural Oncology operates within the rapidly evolving biotechnology industry, specifically focusing on cancer immunotherapy. The market for cancer immunotherapies is experiencing significant growth, driven by advancements in understanding the tumor microenvironment and the potential for durable responses. Key trends include the development of personalized therapies, combination approaches, and novel targets. Mural Oncology's focus on interleukin-based therapies positions it within a competitive landscape that includes major pharmaceutical companies and specialized biotech firms. The company's success will depend on its ability to differentiate its therapies through improved efficacy, safety, and patient selection.
Who Are MURA's Key Customers?
- Cancer patients with mucosal melanoma.
- Cancer patients with platinum-resistant ovarian cancer.
- Healthcare providers and oncologists prescribing cancer treatments.
- Hospitals and cancer centers administering therapies.
- Potential pharmaceutical partners for licensing and commercialization.
How Mural Oncology plc Is Valued
Mural Oncology plc carries a market capitalization of $35.4M, placing it in the micro-cap category.
Company Profile
Mural Oncology plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO Caroline J. Loew. MURA has traded publicly since 2023.
Financial Health
Mural Oncology plc's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.23 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Mural Oncology plc revenue of about $10.2M for fiscal 2026, with EPS near $-0.39.
Insider Activity
The most recent 12 insider filings for Mural Oncology plc break down as 12 sales and 0 purchases. On net that is roughly 985K shares disposed (about $3.9M), a signal worth weighing alongside the fundamentals.
MURA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Novel immunotherapy pipeline.
- Lead product candidate in clinical development.
- Experienced management team.
- Focus on unmet needs in oncology.
Bear Case
- Clinical-stage company with no approved products.
- Limited financial resources.
- High dependence on clinical trial outcomes.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MURA Latest News
No recent news available for MURA.
Leadership: Caroline J. Loew
CEO
Caroline J. Loew serves as the Chief Executive Officer of Mural Oncology Plc, bringing extensive experience in the biopharmaceutical industry. Her career includes leadership roles in both large pharmaceutical companies and smaller biotech firms. Prior to joining Mural Oncology, she held key positions at Alkermes plc, where she played a significant role in the development and commercialization of several successful products. Loew holds advanced degrees in biology and business administration, providing her with a strong foundation in both the scientific and business aspects of the pharmaceutical industry.
Track Record: Since assuming the role of CEO at Mural Oncology, Caroline J. Loew has focused on advancing the company's clinical pipeline and building a strong team. Key milestones under her leadership include the initiation of clinical trials for nemvaleukin alfa and the establishment of strategic partnerships. Her strategic vision is centered on developing innovative immunotherapies that address unmet needs in oncology, with a focus on delivering value to patients and shareholders.
Mural Oncology plc Healthcare Stock: Key Questions Answered
What happened to Mural Oncology plc (MURA) stock?
Mural Oncology plc (MURA) no longer trades on public markets. It was delisted in December 2025. The figures below are historical and are not a current quote.
Can I still buy MURA shares?
No. MURA stopped trading on public markets in December 2025, so the shares are not available through a broker. Anything you see quoted for MURA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MURA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Mural Oncology plc. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Mural Oncology plc do?
Mural Oncology plc is a clinical-stage biotechnology company focused on discovering and developing innovative immunotherapies for the treatment of cancer. The company's lead product candidate, nemvaleukin alfa, is being developed as a monotherapy for mucosal melanoma and in combination with pembrolizumab for platinum-resistant ovarian cancer. Mural Oncology also has programs focused on engineered interleukin-18 and tumor-targeted interleukin-12.
What are the main risks for MURA?
Mural Oncology faces several key risks inherent to the biotechnology industry. The most significant risk is the potential failure of clinical trials for its lead product candidate, nemvaleukin alfa, or other pipeline programs. Clinical trial failures can result in significant financial losses and delays in product development. Additionally, the company faces competition from established pharmaceutical companies with approved oncology therapies.
What is Mural Oncology plc's drug pipeline status?
Mural Oncology plc's primary focus is on advancing nemvaleukin alfa through clinical trials. Nemvaleukin alfa is currently being evaluated as a monotherapy for mucosal melanoma and in combination with pembrolizumab for platinum-resistant ovarian cancer. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs, which are in earlier stages of development.
What are the key growth opportunities for MURA in healthcare?
Mural Oncology plc's growth opportunities lie in the expansion of its immunotherapy pipeline and the successful commercialization of its lead product candidates. Key areas for growth include expanding the application of nemvaleukin alfa to other cancer types, advancing the engineered interleukin-18 and tumor-targeted interleukin-12 programs, and establishing strategic partnerships with larger pharmaceutical companies.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for MURA. Financial data is limited.